Talis Biomedical Corporation

TLIS Healthcare Medical Devices

Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.

2.84 0.00 0.00%
Market cap
$46.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−9.10
Beneish M
−4.89
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '23 Dec '23 Mar '24 Jun '24
Total current assets
89.53 77.68 71.17 63.60
Total non-current assets
17.70 16.99 11.32 9.10
Total Assets
107.23 94.67 82.49 72.70
Total current liabilities
8.45 8.77 9.47 8.20
Total non-current liabilities
17.22 16.79 16.34 15.88
Total liabilities
25.67 25.56 25.81 24.07
Common Equity (Total)
81.55 69.11 56.68 48.62
Shareholders Equity (Total)
81.56 69.12 56.68 48.63
Total Debt
20.08 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates